CHA Medical & Bio Group officially began construction of its Cell Gene Biobank (CGB) facility in Pangyo, South Korea. Investing over $250 million in the project, the new 710,000 ft² site will comprise one of the world’s largest single facilities for cell and gene therapy manufacturing and advanced stem cell biobanking. The construction of the state-of-art facility is expected to be completed by the end of 2024.

Within the facility, the space dedicated for cell and gene therapy will offer integrated CDMO services for mRNA, viral vectors, and plasmid DNA, providing GMP production with multiple segregated cleanrooms to deliver greater manufacturing efficiency. The stem cell biobank will be designed to store various cell types including stem cells, NK cells, cord blood, sperm cells, and egg cells.

At its new CGB facility, CHA Medical & Bio Group will integrate its proprietary cell separation, cell culture, and cryopreservation technologies with its wide range of services to provide more optimized and customized approaches to cell and gene therapy development.

Upon its completion, CGB will act as a key growth engine of CHA Medical & Bio Group’s CDMO business. Together with Matica Biotechnology, Inc., the company’s affiliate cell and gene therapy expert CDMO in the U.S., CHA Medical & Bio Group aims to establish a differentiated strategy for building a strong, global CDMO network.